Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of NHWD-870 HCl in relapsed or refractory diffuse large B-cell lymphoma
CTR20231874Phase 2Active
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NHWD-870 in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd. Primary endpoint: Objective response rate. Started Nov 2023; status: active.
02
Drugs
NHWD-870
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20231874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231874.